Regeneron Pharmaceuticals Inc. said Monday that U.S. authorities placed the company's drug clinical development of osteoarthritis pain on hold after a patient in the trial of another company has developed a serious bone disorder.
Regeneron said, and its partner, Sanofi-Aventis SA, was reported last week by the U.S. Food And Drug Administration that the drug REGN475/SAR164877, was suspended after a patient in the trial of another company to develop a joint avascular necrosis.
This condition is caused when bone tissue dies because of lack of blood supply, causing the collapse of the bones.
Regeneron drug is designed to work by blocking a protein called nerve growth factor (NGF), which is associated with pain. An inhibitor of NGF under development by Pfizer Inc were put on hold earlier this year after some patients have had joint replacement surgery.
The FDA believes that security problems can affect an entire class of anti-NGF.
Decision Resources, a company of advice for health care, initially planned global sales peak tanezumab Pfizer drug could reach $ 1.2 billion, but reduced the forecast of $ 200 million after being put on hold clinical .
Tanezumab was the most advanced class and a cloud cast setback for the development of other drugs, including Regeneron's. Johnson & Johnson and Abbott Laboratories each of the first programs of dumping NGF.
Regeneron shares fell 0.7 percent, to $ 33.27 in midmorning trading on the Nasdaq, in line with a decline of 0.6 percent of the Nasdaq biotechnology.
Regeneron said that currently there is no drug test with registration or who are treating patients.
Regeneron said, and its partner, Sanofi-Aventis SA, was reported last week by the U.S. Food And Drug Administration that the drug REGN475/SAR164877, was suspended after a patient in the trial of another company to develop a joint avascular necrosis.
This condition is caused when bone tissue dies because of lack of blood supply, causing the collapse of the bones.
Regeneron drug is designed to work by blocking a protein called nerve growth factor (NGF), which is associated with pain. An inhibitor of NGF under development by Pfizer Inc were put on hold earlier this year after some patients have had joint replacement surgery.
The FDA believes that security problems can affect an entire class of anti-NGF.
Decision Resources, a company of advice for health care, initially planned global sales peak tanezumab Pfizer drug could reach $ 1.2 billion, but reduced the forecast of $ 200 million after being put on hold clinical .
Tanezumab was the most advanced class and a cloud cast setback for the development of other drugs, including Regeneron's. Johnson & Johnson and Abbott Laboratories each of the first programs of dumping NGF.
Regeneron shares fell 0.7 percent, to $ 33.27 in midmorning trading on the Nasdaq, in line with a decline of 0.6 percent of the Nasdaq biotechnology.
Regeneron said that currently there is no drug test with registration or who are treating patients.

Comments
Post a Comment